Literature DB >> 25448238

Rethinking the discharge policy for Ebola convalescents in an accelerating epidemic.

Tim O'Dempsey, S Humarr Khan, Daniel G Bausch.   

Abstract

The outbreak of Ebola virus disease (EVD) in West Africa has outstripped available resources. Novel strategies are desperately needed to streamline operations. The present norm of requiring negative results on polymerase chain reaction for EVD convalescent patients to be discharged is not evidence-based and often results in asymptomatic patients competing for beds in dangerously crowded Ebola Treatment Units, posing risks to ward staff and patients and the community if infected persons are turned away. We summarize the relevant data and call for a change in discharge criteria for convalescent patients that can safely help reduce the strain on resources and direct energies where they are most needed. In the longer term, research is needed to assess the true infectivity of EVD convalescent patients to establish evidence-based criteria and guidelines for discharge. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Year:  2014        PMID: 25448238      PMCID: PMC4347320          DOI: 10.4269/ajtmh.14-0719

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


The outbreak of Ebola virus disease (EVD) in West Africa has been declared a public health emergency of international concern by the World Health Organization (WHO),1 in large part because the scale of the outbreak has outstripped available resources.2,3 We believe that a change in the discharge policy for convalescent patients can help reduce the strain on resources and direct energies where they are most needed. In the last 15 years mobile laboratories have been routinely installed in epidemic areas to perform diagnostic testing for EVD by testing of blood by real-time polymerase chain reaction (PCR). With the assay at hand, patient discharge criteria of being asymptomatic for 3 days and testing PCR negative has become the norm.4 In our experience providing patient care at Ebola Treatment Units (ETUs) in Sierra Leone and Guinea during this outbreak, the interval between a patient becoming asymptomatic and testing PCR negative varies widely. In many cases completely asymptomatic convalescent patients wait days or even weeks to be released, either because their PCR result remains positive, often at a very low level, or simply because the laboratory is too over-run with samples from suspected new cases to perform the assay on the convalescents. Meanwhile, in many ETUs suspected cases are being turned away because of a critical shortage of beds; we faced this situation in the ETU at Kenema Government Hospital, Sierra Leone, in July 2014, when ∼25% of the official bed capacity was occupied by asymptomatic but PCR-positive patients, usually very impatient to go home. Wards became dangerously overcrowded and increasingly hazardous for staff and patients, deterring EVD cases from being admitted to the Kenema ETU, creating a backlog of EVD-confirmed cases in peripheral holding units, which necessitated diversion of cases to the already over-crowded ETU run by Medicine Sans Frontieres in neighboring Kailahun District. In addition to the operational challenges caused, there is little justification of the PCR-negative requirement on scientific grounds. The viral load in EVD closely parallels the clinical status5 and is thus logically very low in asymptomatic persons. In contrast, symptomatic patients, particularly when severely ill, have high viral loads and are very infectious, posing a far greater community transmission threat.5,6 No secondary transmission was noted in a study of 152 household contacts of 29 convalescent EVD patients followed for up to 21 months after illness.7 All 481 specimens (85 tears, 84 sweat, 79 feces, 95 urine, 86 saliva, 8 semen, 44 vaginal secretions) taken from the convalescent patients between Days 12 and 157 after the onset of illness tested negative by both PCR and cell culture, with the exception of a few PCR-positive results from semen, consistent with the gonads being an immunologically protected site where persistence for months after infection has been recognized.5,8 Furthermore, PCR positivity does not necessarily indicate the presence of infectious virus, but may simply indicate residual nucleic acids being cleared. Cell culture results are very often negative on PCR-positive specimens.8,9 The epidemic has continued to accelerate dramatically in West Africa. Many areas of Liberia and Sierra Leone have passed tipping points in which ETUs can no longer accommodate the case load and measures are being implemented for community-based management. Bed capacity has reached a critical level in some areas. Novel but evidence-based strategies are desperately needed to streamline operations to meet this challenge. To reduce the community “viral load” and optimize use of limited bed and laboratory capacity, we recommend that convalescent patients should be discharged if asymptomatic for 48 hours and independently mobile, with appropriate counseling regarding possible infection risk and a basic discharge kit for infection control. This approach will have the additional benefit of enabling already constrained EVD testing laboratories to focus primarily on testing of new cases, thereby increasing the rate at which EVD PCR-negative suspect cases are identified and discharged, reducing the risk of ward-based EVD transmission to these individuals and freeing up additional beds. More conservative policies requiring blood or even urine to be reverse transcription-PCR (RT-PCR) negative before discharge may be maintained in centers and laboratories where capacity remains sufficient to perform such testing without unduly impacting the flow of patients. In the longer term, research is needed to establish evidence-based criteria and guidelines for safe discharge. This research must include collection of a wide range of bodily fluids from convalescent EVD patients and the testing of samples by both RT-PCR and, importantly, cell culture to detect infectious virus.
  7 in total

1.  Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995.

Authors:  T G Ksiazek; P E Rollin; A J Williams; D S Bressler; M L Martin; R Swanepoel; F J Burt; P A Leman; A S Khan; A K Rowe; R Mukunu; A Sanchez; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

2.  Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidémies à Kikwit.

Authors:  S F Dowell; R Mukunu; T G Ksiazek; A S Khan; P E Rollin; C J Peters
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

3.  Ebola--underscoring the global disparities in health care resources.

Authors:  Anthony S Fauci
Journal:  N Engl J Med       Date:  2014-08-13       Impact factor: 91.245

4.  Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995.

Authors:  L L Rodriguez; A De Roo; Y Guimard; S G Trappier; A Sanchez; D Bressler; A J Williams; A K Rowe; J Bertolli; A S Khan; T G Ksiazek; C J Peters; S T Nichol
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

5.  Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Epidémies à Kikwit.

Authors:  A K Rowe; J Bertolli; A S Khan; R Mukunu; J J Muyembe-Tamfum; D Bressler; A J Williams; C J Peters; L Rodriguez; H Feldmann; S T Nichol; P E Rollin; T G Ksiazek
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

6.  Assessment of the risk of Ebola virus transmission from bodily fluids and fomites.

Authors:  Daniel G Bausch; Jonathan S Towner; Scott F Dowell; Felix Kaducu; Matthew Lukwiya; Anthony Sanchez; Stuart T Nichol; Thomas G Ksiazek; Pierre E Rollin
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

7.  Outbreak of ebola virus disease in Guinea: where ecology meets economy.

Authors:  Daniel G Bausch; Lara Schwarz
Journal:  PLoS Negl Trop Dis       Date:  2014-07-31
  7 in total
  5 in total

1.  Clinical Management of Ebola Virus Disease in the United States and Europe.

Authors:  Timothy M Uyeki; Aneesh K Mehta; Richard T Davey; Allison M Liddell; Timo Wolf; Pauline Vetter; Stefan Schmiedel; Thomas Grünewald; Michael Jacobs; Jose R Arribas; Laura Evans; Angela L Hewlett; Arne B Brantsaeter; Giuseppe Ippolito; Christophe Rapp; Andy I M Hoepelman; Julie Gutman
Journal:  N Engl J Med       Date:  2016-02-18       Impact factor: 91.245

2.  Interpretation of Negative Molecular Test Results in Patients With Suspected or Confirmed Ebola Virus Disease: Report of Two Cases.

Authors:  Jeffrey K Edwards; Christian Kleine; Vincent Munster; Ruggero Giuliani; Moses Massaquoi; Armand Sprecher; Daniel S Chertow
Journal:  Open Forum Infect Dis       Date:  2015-09-19       Impact factor: 3.835

3.  Follow-up of Ebola Patient, 2014-2015.

Authors:  Venkatesh Srinivas; Pragya Yadav; Veena Mittal; Gouri Chaubal; Mala Chhabra; Sanjay Mattoo; Arvind Rai; Devendra T Mourya
Journal:  Emerg Infect Dis       Date:  2016-04       Impact factor: 6.883

4.  Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.

Authors:  Stuart D Dowall; Andrew Bosworth; Emma Rayner; Irene Taylor; John Landon; Ian Cameron; Ruth Coxon; Ibrahim Al Abdulla; Victoria A Graham; Graham Hall; Gary Kobinger; Roger Hewson; Miles W Carroll
Journal:  Sci Rep       Date:  2016-07-28       Impact factor: 4.379

5.  Meta-analysis of predictive symptoms for Ebola virus disease.

Authors:  Vageesh Jain; Andre Charlett; Colin S Brown
Journal:  PLoS Negl Trop Dis       Date:  2020-10-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.